Do Alpha-Ketoanalogues Slow Down Disease Progression in Non-Dialysis Dependent Chronic Kidney Disease?
Objective: To observe the effectiveness of keto-analogues in slowing down the disease progression in non-dialysis dependent CKD patients. Study Design: Quasi-experimental study. Place and Duration of Study: The study was carried out at Nephrology Department of Combined Military Hospital (CMH), Pesh...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
National University of Medical Sciences
2023-10-01
|
| Series: | Life and Science |
| Subjects: | |
| Online Access: | https://ojs.lifenscience.org/index.php/life-and-science/article/view/407 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850199740115845120 |
|---|---|
| author | Bilal Saeed khayam . Zabihullah Afridi Muhammad Sana Ullah |
| author_facet | Bilal Saeed khayam . Zabihullah Afridi Muhammad Sana Ullah |
| author_sort | Bilal Saeed |
| collection | DOAJ |
| description | Objective: To observe the effectiveness of keto-analogues in slowing down the disease progression in non-dialysis dependent CKD patients.
Study Design: Quasi-experimental study.
Place and Duration of Study: The study was carried out at Nephrology Department of Combined Military
Hospital (CMH), Peshawar, Pakistan from August 2022 to 28 February 2023.
Methods: Data was collected on 290 kidney disease improving global outcomes (KDIGO) stage 3 and 4 CKD
patients through non-probability consecutive sampling technique. The cohort was divided into group A (Low
protein diet) and B (ketodiet). Group A received low protein diet in addition to standard chronic disease
treatment while Group B was labelled as keto-diet group which received ketoanalogues in addition to low
protein diet and standard chronic kidney disease treatment. Baseline and six months eGFR was calculated and
compared for both groups. SPSS version 23.00 was used for data analysis. The P value ≤ 0.05 was considered
significant.
Results: 286 patients aged 51.84±18.127 were selected for our study. 188(65.73%) were males while females
were 98 (34.26%). There were 142 (50.34%) and 144(50.34%) patients in group A and B respectively. Duration of
CKD in group A and B was 6.45±2.55 and 6.49±1.75 years respectively. The means difference of eGFR in group A
(low protein diet) at baseline and after six months was 3.64±1.09mL/ min/ 1.73m2 while that of group B was
1.48±0.41 mL/ min/ 1.73m2 (P-value<0.000).
Conclusion: Ketoanalogues is an emerging therapy which slows down disease progression in non-dialysis
dependent CKD patients. Although its use is recommended by some clinicians in CKD stage 3 and 4 non-dialysis
dependent but still controversial.
How to cite this: Saeed B, Khayam, Afridi Z, Ullah MS. Do Alpha-Ketoanalogues Slow Down Disease Progression in Non-Dialysis Dependent Chronic Kidney Disease?. Life and Science. 2023; 4(4): 427-431. doi: http://doi.org/10.37185/LnS.1.1.407 |
| format | Article |
| id | doaj-art-76c95b4f9d7145bb90e52915a141e1f5 |
| institution | OA Journals |
| issn | 2521-0475 2708-2970 |
| language | English |
| publishDate | 2023-10-01 |
| publisher | National University of Medical Sciences |
| record_format | Article |
| series | Life and Science |
| spelling | doaj-art-76c95b4f9d7145bb90e52915a141e1f52025-08-20T02:12:33ZengNational University of Medical SciencesLife and Science2521-04752708-29702023-10-01445510.37185/LnS.1.1.407407Do Alpha-Ketoanalogues Slow Down Disease Progression in Non-Dialysis Dependent Chronic Kidney Disease?Bilal Saeed0khayam .1Zabihullah Afridi2Muhammad Sana Ullah3Combined Military Hospital (CMH) Peshawar, PakistanCombined Military Hospital (CMH), Peshawar, PakistanCombined Military Hospital (CMH), Peshawar, PakistanKhyber Teaching Hospital, Peshawar, PakistanObjective: To observe the effectiveness of keto-analogues in slowing down the disease progression in non-dialysis dependent CKD patients. Study Design: Quasi-experimental study. Place and Duration of Study: The study was carried out at Nephrology Department of Combined Military Hospital (CMH), Peshawar, Pakistan from August 2022 to 28 February 2023. Methods: Data was collected on 290 kidney disease improving global outcomes (KDIGO) stage 3 and 4 CKD patients through non-probability consecutive sampling technique. The cohort was divided into group A (Low protein diet) and B (ketodiet). Group A received low protein diet in addition to standard chronic disease treatment while Group B was labelled as keto-diet group which received ketoanalogues in addition to low protein diet and standard chronic kidney disease treatment. Baseline and six months eGFR was calculated and compared for both groups. SPSS version 23.00 was used for data analysis. The P value ≤ 0.05 was considered significant. Results: 286 patients aged 51.84±18.127 were selected for our study. 188(65.73%) were males while females were 98 (34.26%). There were 142 (50.34%) and 144(50.34%) patients in group A and B respectively. Duration of CKD in group A and B was 6.45±2.55 and 6.49±1.75 years respectively. The means difference of eGFR in group A (low protein diet) at baseline and after six months was 3.64±1.09mL/ min/ 1.73m2 while that of group B was 1.48±0.41 mL/ min/ 1.73m2 (P-value<0.000). Conclusion: Ketoanalogues is an emerging therapy which slows down disease progression in non-dialysis dependent CKD patients. Although its use is recommended by some clinicians in CKD stage 3 and 4 non-dialysis dependent but still controversial. How to cite this: Saeed B, Khayam, Afridi Z, Ullah MS. Do Alpha-Ketoanalogues Slow Down Disease Progression in Non-Dialysis Dependent Chronic Kidney Disease?. Life and Science. 2023; 4(4): 427-431. doi: http://doi.org/10.37185/LnS.1.1.407https://ojs.lifenscience.org/index.php/life-and-science/article/view/407chronic kidney disease, estimated glomerular filtration rate, protein restricted diet, supplements |
| spellingShingle | Bilal Saeed khayam . Zabihullah Afridi Muhammad Sana Ullah Do Alpha-Ketoanalogues Slow Down Disease Progression in Non-Dialysis Dependent Chronic Kidney Disease? Life and Science chronic kidney disease, estimated glomerular filtration rate, protein restricted diet, supplements |
| title | Do Alpha-Ketoanalogues Slow Down Disease Progression in Non-Dialysis Dependent Chronic Kidney Disease? |
| title_full | Do Alpha-Ketoanalogues Slow Down Disease Progression in Non-Dialysis Dependent Chronic Kidney Disease? |
| title_fullStr | Do Alpha-Ketoanalogues Slow Down Disease Progression in Non-Dialysis Dependent Chronic Kidney Disease? |
| title_full_unstemmed | Do Alpha-Ketoanalogues Slow Down Disease Progression in Non-Dialysis Dependent Chronic Kidney Disease? |
| title_short | Do Alpha-Ketoanalogues Slow Down Disease Progression in Non-Dialysis Dependent Chronic Kidney Disease? |
| title_sort | do alpha ketoanalogues slow down disease progression in non dialysis dependent chronic kidney disease |
| topic | chronic kidney disease, estimated glomerular filtration rate, protein restricted diet, supplements |
| url | https://ojs.lifenscience.org/index.php/life-and-science/article/view/407 |
| work_keys_str_mv | AT bilalsaeed doalphaketoanaloguesslowdowndiseaseprogressioninnondialysisdependentchronickidneydisease AT khayam doalphaketoanaloguesslowdowndiseaseprogressioninnondialysisdependentchronickidneydisease AT zabihullahafridi doalphaketoanaloguesslowdowndiseaseprogressioninnondialysisdependentchronickidneydisease AT muhammadsanaullah doalphaketoanaloguesslowdowndiseaseprogressioninnondialysisdependentchronickidneydisease |